Pharmacogenomic Study to Predict Antidepressant Responsiveness in Depressed Patients
Overview
- Phase
- N/A
- Intervention
- SSRI treated group
- Conditions
- Depression
- Sponsor
- Samsung Medical Center
- Enrollment
- 1000
- Locations
- 1
- Primary Endpoint
- Antidepressant Response at 2,4,6 weeks A/E monitoring at 1,2,4,6 weeks
- Last Updated
- 10 years ago
Overview
Brief Summary
The purpose of this study is to determine whether pharmacogenomic study predict antidepressant responsiveness in advance before the appearance of the drug effects until 4~6 weeks after drug administration.
Detailed Description
The purpose of this study is 1. to determine whether genomic effects on antidepressant response differed by class of drug, 2. whether genomic differences between drug responders and nonresponders predict the response of antidepressant and 3. to construct the prediction model for antidepressant treatment in order to aid to select the their genetically matching drugs.
Investigators
Doh Kwan Kim
M.D., pHD
Samsung Medical Center
Eligibility Criteria
Inclusion Criteria
- •Eligible patients were enrolled in the clinical trials program of hte Samsung Medical Center Geropsychiatry and Affective Disorder Clinics(Seoul, Korea). They received a semistructured diagnostic interview, the Samsung Psychiatric Evaluation Schedule. The affective disorder section of the Samsung Psychiatric Evaluation Schedule uses the Korean version of the structured clinical interview for the diagnostic and statistical manual of mental disorders, Fourth edition.
- •interview with one more patient's family member for objective diagnosis and final diagnosis decision by agreements of two more psychiatric physicians
Exclusion Criteria
- •received psychotropic medication within 2 weeks of the study or fluoxetine within 4 weeks
- •potential study participants for pregnancy, significant medical conditions, abnormal laboratory baseline values, unstable psychiatric features(eg.suicidal), history of alcohol of drug dependence, seizures, head trauma with loss of consciousness, neurological illness, or concomitant Axis I psychiatric disorder.
Arms & Interventions
SSRI treated group
SSRI treated group is depressive patients treated with fluoxetine, paroxetine, or sertraline
Intervention: SSRI treated group
non-SSRI treated group
non-SSRI treated group is depressive patients treated with milnacipran, venlafaxine, nortriptyline, or mirtazapine
Intervention: non-SSRI treated group
Outcomes
Primary Outcomes
Antidepressant Response at 2,4,6 weeks A/E monitoring at 1,2,4,6 weeks
Time Frame: 6 weeks
Secondary Outcomes
- Biological value at 0 and 6 weeks(6weeks)